摘要
目的应用表面增强激光解析／电离化时间-飞行质谱技术（SELDI—TOF MS）检测乳腺癌患者新辅助化疗前的癌组织蛋白质谱的差异，筛选有疗效预测价值的相关蛋白。方法用SELDI—TOF MS技术检测30例乳腺癌治疗前的癌组织标本，获得蛋白质谱，行新辅助化疗后，根据RECIST标准评价疗效，分为新辅助化疗有效组（CR＋PR，19例）和无效组（SD＋PD，11例），比较2组蛋白质谱差异。结果2组比较，筛选出11个蛋白峰差异有统计学意义（P〈0．05），分别为：3491Da（t=3．189，P=0．004）、5158Da（t=3．897，P=0．001）、5360Da（t=2．157，P=0．04）、7549Da（t=2．173，P=0．038）、8451Da（t=2．258，P：0．032）、8694Da（t=3．234，P=0．003）、9089Da（t=2．653，P=0．013）、10528Da（t=3．127，P=0．004）、13445Da（t=2．231，P=0．034）、15118Da（t=3．255，P=0．003）、44065Da（t=2．554，P=0．017）。这些蛋白峰强度有效组均较无效组高。结论应用SELDI—TOFMS技术可筛选出乳腺癌化疗敏感相关的组织蛋白质谱。
Objective To find out related proteins that could possibly predict curative effects of neoadjuvant chemotherapy（NACT） by applying surface-enhanced laser desorption/ionization time-of-flight mass spectrum- etry（ SELDI-TOF MS） to detect the difference in protein spectrum of breast cancer tissues. Methods Cancer tissue samples from 30 cases of breast cancer patients were detected by SELDI-TOF MS before NACT to get protein spectrum of breast cancer tissues. After NACT, the curative effects were evaluated according to RECIST standard and patients were divided into effective group（ 19 cases with complete response or partial response）and invalid group（ 11 cases with stable disease or progressive disease）. Results 11 different protein peaks （ P 〈 0. 05 ） were screened out：3491 Da（t =3. 189 P =0. 004）, 5158 Da（t =3. 897 P =0.001）, 5360 Da（t =2. 157 P =0. 04）, 7549 Da（t=2.173 P=0.038）,8451 Da（t=2.258 P=0.032）, 8694 Da（t=3.234 P=0.003）, 9089 Da （t =2.653 P=0.013）, 10528 Da（t =3. 127 P =0.004）, 13445 Da（t =2.231 P =0.034）, 15118 Da（t= 3. 255 P =0. 003）, and 44065 Da（t =2. 554 P =0. 017）. They were all expressed higher in effective group than in invalid group. The difference had statistical significance（P 〈 0. 05 ）. Conclusion SELDI-TOF MS technology can screen out protein spectrum sensitive to NACT, providing evidences for breast cancer patients whether or not taking NACT.
出处
《中华内分泌外科杂志》
CAS
2013年第1期42-45,共4页
Chinese Journal of Endocrine Surgery
基金
山东省自然科学基金（y2008c15）
